Ever since the increased understanding of its role in curbing the overactivity of the mTOR pathway [7] and incidental discovery of potential therapeutic effect in cardiac rhabdomyoma in a child receiving mTORi for SEGA in 2011 [9], these agents have been increasingly accepted as effective therapeutic options for symptomatic cardiac rhabdomyoma. The gene discussed is MTOR; the disease is cardiac rhabdomyoma.